ORIONS Money Stocks

[BioSpecialist]

CTX.TO =MC $13 M /PROFITABLE Pharma with many marketed products and a strong pipeline ..Undiscovered company with BRUTAL upside potential


Prsentation
http://www.crescitatherapeutics.com/wp-content/uploads/2019/11/Investor-Presentation-Nov-2019a.pdf


"Crescita Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Studies for its Lead Pipeline Product in Patients with Plaque Psoriasis"
https://www.prnewswire.com/news-releases/crescita-announces-positive-topline-results-from-two-pivotal-phase-3-clinical-studies-for-its-lead-pipeline-product-in-patients-with-plaque-psoriasis-301002807.html


Crescita (TSX:CTX) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. Crescita owns a portfolio of non-prescription skincare products and has one FDA approved prescription product, Pliaglis that is licensed globally to Galderma SA and Taro Pharmaceuticals for the U.S. market. Crescita owns the sales and marketing rights in Canada and Mexico.